Longeveron Inc
LGVN0.765USD
-0.035-4.36%
交易中 （美東）報價延遲15分鐘
11.56M總市值
虧損本益比TTM
關於 Longeveron Inc 公司
Longeveron Inc. 是一家臨牀階段的生物技術公司。該公司專注於開發針對特定衰老相關和危及生命的疾病的細胞療法。該公司的主要研究產品是 LOMECEL-B 細胞療法產品 (Lomecel-B)，該產品源自培養擴增的藥用信號細胞 (MSC)，這些細胞來源於年輕健康成人捐贈者的骨髓。該公司主要專注於三種管線適應症，包括左心發育不全綜合徵 (HLHS)、阿爾茨海默病 (AD) 和衰老相關虛弱症。其 Lomecel-B 具有多種作用機制，包括促血管、促再生、抗炎和組織修復和癒合作用，可在一系列疾病領域中應用。該公司與兩家供應商簽訂了骨髓供應合同：俄克拉荷馬州血液研究所和 Vista Health Research。
Longeveron Inc簡介
公司代碼LGVN
公司名稱Longeveron Inc
上市日期Feb 12, 2021
CEOMr. Wa'el Hashad
員工數量25
證券類型Ordinary Share
年結日Feb 12
公司地址1951 NW 7th Ave
城市MIAMI
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編33136
電話13053027158
網址https://www.longeveron.com/
公司代碼LGVN
上市日期Feb 12, 2021
CEOMr. Wa'el Hashad
Longeveron Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.42K
-7.23%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
140.15K
-7.82%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
102.54K
-6.91%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
41.36K
+39.76%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Ms. Neha Motwani
Ms. Neha Motwani
Independent Director
Independent Director
21.00K
+425.00%
Dr. George Paletta
Dr. George Paletta
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.42K
-7.23%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
140.15K
-7.82%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
102.54K
-6.91%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
41.36K
+39.76%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
業務USD
名稱
營收
佔比
Clinical trial revenue
298.00K
94.30%
Contract manufacturing
12.00K
3.80%
Contract manufacturing lease revenue
6.00K
1.90%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Clinical trial revenue
298.00K
94.30%
Contract manufacturing
12.00K
3.80%
Contract manufacturing lease revenue
6.00K
1.90%
股東統計
更新時間: 10月29日 週三
更新時間: 10月29日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Lincoln Alternative Strategies LLC
6.01%
Armistice Capital LLC
3.45%
Lehr (Paul T)
1.66%
Hashad (Mohamed Wa'el Ahmed)
1.59%
Hare (Joshua M)
1.29%
其他
85.99%
持股股東
持股股東
佔比
Lincoln Alternative Strategies LLC
6.01%
Armistice Capital LLC
3.45%
Lehr (Paul T)
1.66%
Hashad (Mohamed Wa'el Ahmed)
1.59%
Hare (Joshua M)
1.29%
其他
85.99%
股東類型
持股股東
佔比
Individual Investor
9.26%
Corporation
6.01%
Hedge Fund
3.96%
Investment Advisor
1.66%
Investment Advisor/Hedge Fund
1.09%
Venture Capital
0.25%
Bank and Trust
0.02%
其他
77.75%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
58
1.37M
6.98%
+569.67K
2025Q2
73
2.18M
16.11%
+296.38K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lincoln Alternative Strategies LLC
1.18M
6.01%
+1.18M
--
Aug 08, 2025
Armistice Capital LLC
676.23K
3.45%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
330.30K
2.42%
+100.44K
+43.69%
Jul 15, 2025
Hashad (Mohamed Wa'el Ahmed)
310.90K
1.59%
+166.85K
+115.83%
Jul 15, 2025
Hare (Joshua M)
253.07K
1.29%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
179.52K
0.92%
+17.00K
+10.46%
Jul 15, 2025
Locklear (Lisa)
164.30K
0.85%
+11.77K
+7.71%
Aug 11, 2025
The Vanguard Group, Inc.
144.27K
0.74%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
141.50K
0.72%
+770.00
+0.55%
Jun 30, 2025
Agafonova (Nataliya)
152.03K
1.12%
+94.57K
+164.57%
Jul 15, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
公告日期
類型
比率
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
